) recently announced that it has entered into a license agreement
with Biocare Medical, LLC, through one of its wholly-owned
subsidiaries, Ventana Medical Systems, Inc.
Ventana Medical manufactures instruments and reagents that
automate tissue processing and slide staining for cancer
diagnostics. As per the agreement, Biocare will access certain
patents and materials related to p63 diagnostics in the research
and IVD field.
Concurrently, Biocare settled its dispute related to the p63
technology with privately-held AsymmetRx Medical, Inc. Hence,
Biocare has gained a worldwide license to distribute p63 (4A4)
mouse monoclonal primary antibody in both the research and IVD
markets from Roche.
Meanwhile, AsymmetRx will terminate all patent infringement
litigation. As per the Harvard Medical School patent filings,
AsymmetRx currently holds the license for the use of P63
antibody, which primarily helps in the diagnosis of prostate and
We note that the dispute started in Jun 2007 when AsymmetRx
initiated litigation challenging Biocare's intellectual property
license for p63.
We remind investors that in Jun 2010, Roche signed a license
agreement with AsymmetRx Medical, whereby Roche was granted the
exclusive license and distribution rights of AsymmetRx' patented
We are encouraged by the recent developments at Roche. Most
importantly, the US Food and Drug Administration (FDA) has
approved Roche's Kadcyla (ado-trastuzumab emtansine or T-DM1) a
few days back for the treatment of patients suffering from
HER2-positive metastatic breast cancer (mBC).
Roche has partnered with
) for Kadcyla.
Roche carries a Zacks Rank #4 (Sell). Nevertheless, other
large cap pharma stocks, such as
Eli Lilly and Company
) currently look attractive with a Zacks Rank #2 (Buy).
BAYER A G -ADR (BAYRY): Free Stock Analysis
IMMUNOGEN INC (IMGN): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.